key: cord-1015820-qbljuqfg
authors: Maeda, Mariane de Fátima Yukie; Brizot, Maria de Lourdes; Gibelli, Maria Augusta Bento Cicaroni; Ibidi, Silvia Maria; de Carvalho, Werther Brunow; Hoshida, Mara Sandra; Machado, Clarisse Martins; Sabino, Ester Cerdeira; de Oliveira da Silva, Lea Campos; Jaenisch, Thomas; Mendes‐Correa, Maria Cássia Jacintho; Mayaud, Philippe; Francisco, Rossana Pulcinelli Vieira
title: Vertical transmission of SARS‐CoV2 during pregnancy: A high‐risk cohort
date: 2021-06-14
journal: Prenat Diagn
DOI: 10.1002/pd.5980
sha: be7340be3e07733fa344744274a7d2a2f2ad0607
doc_id: 1015820
cord_uid: qbljuqfg

OBJECTIVE: Identify the potential for and risk factors of SARS‐CoV‐2 vertical transmission. METHODS: Symptomatic pregnant women with COVID‐19 diagnosis in whom PCR for SARS‐CoV‐2 was performed at delivery using maternal serum and at least one of the biological samples: cord blood (CB), amniotic fluid (AF), colostrum and/or oropharyngeal swab (OPS) of the neonate. The association of parameters with maternal, AF and/or CB positivity and the influence of SARS‐CoV‐2 positivity in AF and/or CB on neonatal outcomes were investigated. RESULTS: Overall 73.4% (80/109) were admitted in hospital due to COVID‐19, 22.9% needed intensive care and there were four maternal deaths. Positive RT‐PCR for SARS‐CoV‐2 was observed in 14.7% of maternal blood, 13.9% of AF, 6.7% of CB, 2.1% of colostrum and 3.7% of OPS samples. The interval between COVID‐19 symptoms and delivery was inversely associated with SARS‐CoV‐2 positivity in the maternal blood (p = 0.002) and in the AF and/or CB (p = 0.049). Maternal viremia was associated with positivity for SARS‐CoV‐2 in AF and/or CB (p = 0.001). SARS‐CoV‐2 positivity in the compartments was not associated with neonatal outcomes. CONCLUSION: Vertical transmission is possible in pregnant women with COVID‐19 and a shorter interval between maternal symptoms and delivery is an influencing factor.

Although the burden of coronavirus disease 2019 (COVID-19) for individuals with particular conditions, such as chronic diseases, has been described to some extent, 1 the impact of disease and/or the virus on pregnant women and their offspring is not very well documented. In addition, it is not well known whether the disease at an acute stage or severe disease around the time of delivery have different impacts on pregnancy outcomes and vertical transmission. [2] [3] [4] [5] [6] [7] [8] [9] [10] The co-expression of ACE-2 receptor and TMPRSS2 protease, required for SARS-CoV-2 cellular entry, is not presented at the maternal-fetal interface. However, it is possible that the damage caused by the virus in the placenta, like vascular malperfusion and inflammation, may contribute to disruption of the placental barrier, predisposing to transplacental infection. 11 Therefore, it is reasonable that some conditions related to COVID-19 infection or to the pregnancy could predispose to these changes in the placenta and facilitate the vertical transmission.

Several reports of vertical transmission have been published, mostly based on case reports, case series, or meta-analysis and reviews of such series. [2] [3] [4] 12, 13 Conversely, few studies have systematically investigated the presence of SARS-COV-2 in biological samples such as cord blood (CB), placental tissue, and amniotic fluid (AF) to support the role of vertical transmission. 4, 6, [14] [15] [16] [17] [18] Moreover, the results of these reports have been inconsistent, which may be due to the timing of sample collection (during the acute or post-recovery phase of maternal COVID- 19) , type of assays used to detect the presence of the virus, lack of test accuracy, 19, 20 and the absence of a unique and standardized classification of vertical transmission. 21, 22 Given the lack of data on the potential of, timing, circumstances 

This analysis of vertical transmission is one of the aims of a major cohort study, "exploratory study on COVID-19 in pregnant women," which began on April 12th at Hospital das Clinicas (HC) and Hospital Universitario (HU) of São Paulo University and is ongoing. The exploratory study also included estimating the seroprevalence of SARS-CoV-2 at delivery at HU.

When the COVID-19 pandemic started in São Paulo, our institution organized the HC as a COVID-19 hospital and the HU as a non-COVID-19 hospital. Therefore, pregnant women with COVID-19 or flu symptoms or contact with a SARS-CoV-2-positive person would be seen at HC; others would be seen at HU. In addition, at HU, a triage system at the hospital entrance was established; pregnant women with COVID-19 or flu symptoms or contact with a SARS-CoV-2-positive person were referred immediately to HC at any time during pregnancy, delivery or puerperium. Patients seen at HC 2were only allowed to follow the antenatal or puerperium at HU after 14 days of quarantine and without symptoms.

For the present investigation, pregnant women who fulfilled the following inclusion criteria were selected: (1) singleton pregnancies with live fetuses with a diagnosis of COVID-19 during pregnancy or at delivery by real time polymerase chain reaction (RT-PCR) using a nasopharyngeal swab (NPS) or serology and with symptoms of COVID-19; and (2) investigation of SARS-CoV-2 by RT-PCR using maternal blood and at least one biological sample at delivery (CB, AF) or after birth (colostrum or oropharyngeal swab [OPS] from the neonate).

All symptomatic pregnant women admitted to HC were investigated for SARS-CoV-2 infection by RT-PCR using samples collected from the respiratory tract (nasopharynx and/or trachea) from the third day of symptoms. In cases with negative results, NPS testing was repeated, or SARS-CoV-2 serology was performed after the eighth day of symptoms. A positive RT-PCR or serology was assigned as SARS-CoV-2 infection, considering that all patients had symptoms and that PCR lacks sensitivity in late infections. 20 The following symptoms were considered COVID-19 symptoms: fever or chills, cough, dyspnea, fatigue, myalgia, sore throat, headache, congestion, or runny nose; loss of taste or smell; diarrhea.

At HC, pregnant women with COVID-19 symptoms were evaluated by our clinical staff and hospitalized if they presented any of the following situations: (1) need for clinical support or (2) other obstetric emergencies such as hypertensive disorders, labor, premature rupture of membranes or fetal distress. Severe COVID-19 cases were defined as those who needed supplemental oxygen (because of dyspnea, respiratory frequency ≥24 breaths per minute; and/or oxygen saturation level <95%) or required admission to the intensive care unit. Delivery was indicated based on obstetrics and/or maternal clinical worsening in cases of severe COVID-19. The mode of delivery was chosen according to obstetrics and maternal clinical conditions. To avoid contamination of the neonate, delayed cord clamping and skin-to-skin contact were not allowed in cases of delivery at HC. In addition, neonates were separated from their mothers and other family members, and breastfeeding was not allowed until hospital discharge.

Information on patient demographics and history as well as details of treatments and results from exams were recorded in a REDCap platform database.

The following samples were obtained at delivery from pregnant women with symptoms of COVID-19 during pregnancy or at delivery: maternal blood, CB and AF. Maternal blood samples were collected through venipuncture immediately before delivery. Cord artery or vein blood samples (5-10 ml) were collected by needle puncture after cord clamping. The serum and plasma were separated and aliquoted. AF was collected before the rupture of amniotic membranes via direct needle aspiration using a 20-ml syringe, during cesarean section or vaginal delivery. Within 48 h of delivery, a research staff member collected a 5-ml colostrum sample into a sterile tube after appropriate cleaning of the nipples and breasts. All samples were stored at −80°C until analysis.

For neonates born at HC, a swab was collected from the oropharynx and trachea (if the newborn was intubated), or two samples from the oropharynx were collected at 48 h after delivery for SARS-CoV-2 RT-PCR analysis. In cases of any positive test for the neonate, an additional sample was obtained at 72 h after delivery and tested to exclude false-positive results. Neonates born at HU were not subjected to SARS-CoV-2 investigation, as the mothers were not symptomatic at delivery, and breastfeeding was allowed. A serological test (IgG/IgM antibodies) was performed using the Wondfo One

Step COVID-19 test (Guangzhou Wondfo Biotech). The test was performed using 10 μl of serum pipetted into the sample cavity of the test device, after which 80 μl was added to the cavity below the sample cavity. The result was read in 15 min by three people that had received appropriate training. The color change was compared to the assay standard. 23 For viral culture, Vero cells (ATCC CCL-81) were used as previously described. [24] [25] [26] Vero CCL81 cells were cultured in Dulbecco minimal essential medium supplemented with heat-inactivated fetal bovine serum (10%) and antibiotics/antimycotics (Cultilab).

For virus isolation, samples were inoculated in Vero cell culture in plastic bottles (jet biofilm, 12.5 cm 2 area, 25 ml capacity) immediately after processing. The inoculated cultures were grown in a 37°C incubator in an atmosphere of 5% CO 2 . The cell cultures were maintained for at least 2 weeks and observed daily for evidence of the cytopathic effect. At least two subcultures were performed weekly.

Presumptive detection of virus in supernatants showing cytopathic effect was investigated using an inverted microscope (Nikon) and confirmed by specific RT-PCR as described above.

Quantitative continuous variables are presented as means and standard deviations or medians and minimum and maximum values.

Categorical variables are presented as absolute frequencies and percentages. Comparison between groups was performed using Fisher's exact test for unpaired samples with normal distribution; when the distribution was not normal, the Mann-Whitney U nonparametric test was employed. Differences were considered significant when the p-value was less than 0.05. The data were analyzed MAEDA ET AL. 

Between 12th April and 30th September, 1044 pregnant women were admitted at HC and HU, and 595 pregnant women being assessed; 109 fulfilled the inclusion criteria for the present analysis ( Figure 1 ). Details regarding the demographics, obstetrics and clinical characteristics of the participants are presented in Table 1 . For 108 cases, the median interval between COVID-19 symptoms and delivery was 23.5 days (7.2-76.2). In one case, the patient experienced COVID-19 symptoms during pregnancy but was not able to provide the timing; therefore, this case was not included in this analysis. The majority of this cohort were admitted to hospital due Rates of RT-PCR positivity for SARS-CoV-2 in biological samples collected at delivery were 14.7% (16/109) for maternal blood, 13.9% (6/43) for AF and 6.7% (7/105) for CB. Overall, there were some difficulties regarding the collection of AF due to the severity of some cases and the need to ascertain that the samples were not contaminated with maternal fluids during delivery, which contributed to the small number of AF samples collected. In total, 2.1% (2/97) of the maternal colostrum samples were positive for SARS-CoV-2 by RT-PCR. Viral culture was performed in these two positive cases and did not show viral replication, which may be due to the high fat composition of colostrum, which can render this analysis difficult.

Distributions of SARS-CoV-2 status in the investigated compartments are presented in Table S1 . Details of the cases with at least one positive sample for SARS-CoV-2 are described in Table 2 .

All pregnant women with positive SARS-CoV-2 RT-PCR results for maternal blood at delivery presented COVID-19 symptoms in the third trimester (p = 0.007; Table 3 ). In addition, a significantly shorter interval between the occurrence of COVID-19 symptoms and delivery (7.5 vs. 29 days, p = 0.002) was observed in cases of SARS-CoV-2 positivity in maternal blood, and this result was also observed when considering intervals ≤10 or >10 days (p = 0.006; Table 3 ). Conversely, no influence of other maternal, COVID-19related, or obstetric factors was observed (Table 3) . Table 4 provides the associations of maternal COVID-19 and obstetrics parameters with SARS-CoV-2 RT-PCR positivity in AF and/or CB at delivery. The interval between the onset of COVID-19 symptoms and delivery was associated with positive SARS-CoV-2 RT-PCR results in AF and/or CB at delivery (7 vs. 27 days, p = 0.049), which was also observed for intervals ≤10 or >10 days (p = 0.032; Table 4 ). In addition, SARS-CoV-2 RT-PCR positivity in maternal serum at delivery was associated with SARS-CoV-2 RT-PCR SARS-CoV-2 AF and/or CB among the 54 neonates tested for SARS-CoV-2 (Table 5) . SARS-CoV-2 positivity in AF and/or CB was not associated with neonatal outcomes.

In two neonates ( for the other case, the CB and colostrum samples were positive for SARS-CoV-2 ( Table 2 ).

The two neonates with suspected vertical transmission were born at HC and had the following outcomes ( Table 2 , cases 1 and 2).

The first was a female delivered by caesarean section at 33.57 weeks of gestation due to worsening of the maternal COVID-19 condition.

The 5-min Apgar score was 9, and the birth weight was 2130 g. OPS 

The findings of this prospective study conducted in a single center We acknowledge that despite of the finding that the shorter infection-delivery interval is the main factor for vertical transmission this aspect could also be related to mechanical transmission throughout contamination during delivery. However, we took all the precautions during the samples collections and the newborn was immediately separated from the mother soon after birth.

The major strength of this study is that we evaluated a systematic collection of samples that represents exposure of the neonate. 

In conclusion, our study supports the possibility of vertical transmission of SARS-CoV-2 from infected symptomatic mothers to their T A B L E 5 Association of neonatal parameters according to SARS-CoV-2 RT-PCR positivity in compartments (amniotic fluid and/or cord blood) in cases in which the neonates were tested for SARS-CoV-2 by oropharyngeal swab (N = 54) infants, particularly if infection occurs close to delivery. Therefore, our data suggest that special care is needed in pregnant women with COVID-19 and that whenever possible, delivery in the acute phase of the disease should be avoided.

Pereira for their information technology and administrative support in the project development. This study was supported by CAPES (88881.504727/2020-01) and the European Union's Horizon 2020

Research and Innovation Programme under ZIKAlliance (Grant Agreement No 734548). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The authors declare no conflict of interests.

The study protocol was approved by the ethics committees of both hospitals (CAAE: 30270820.3.0000.0068, approved on April 11th, 2020) and was registered at ClinicalTrial.gov (NCT04647994). All participants provided informed consent before participating in the study.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Mariane de Fátima Yukie Maeda https://orcid.org/0000-0003-3977-4954

Clinical course and risk-factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review

Rates of maternal and perinatal mortality and vertical transmission in pregnancies complicated by severe acute respiratory syndrome coronavirus (SARS-COV-2) infection. A systematic review

Clinical outcomes of 201 neonates born to mother with COVID-19: a systematic review

SARS-CoV-2 Infection in Pregnancy Collaborative Group. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study

Coronavirus disease 2019 in pregnant women: a report based on 116 cases

Coronavirus Disease 2019 (COVID-19) pandemic and pregnancy

Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study

WAPM (World Association of Perinatal Medicine) Working Group on COVID-19. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection

Characteristics and shortterm obstetric outcomes in a case series of 67 women test-positive for SARS-CoV-2 in

Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2s

Vertical transmission of severe acute respiratory syndrome coronavirus 2: a systematic review

Evidence and possible mechanisms of rare maternal-fetal transmission of SARS-CoV-2

Analysis of SARS-CoV-2 vertical transmission during pregnancy

Vertical transmission of COVID-19: a systematic review and meta-analysis

Perinatal transmission of COVID-19 associated SARS-COV-2: should we worry?

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Transplacental transmission of SARS-CoV-2 infection

Detection of SARS-CoV-2 in different types of clinical specimens

Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2

WHO Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2

Classification system and case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates

Performance of a qualitative rapid chromatographic immunoassay to diagnose COVID-19 in patients in a middle-income country

Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections

Growth and maintenance of Vero cell lines

Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient

Neonatal early-onset infection with SARS-COV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China

Maternal and perinatal characteristics and outcomes of pregnancies complicated with COVID-19 in Kuwait

Evaluation for SARS-Cov-2 in breast milk from 18 infected women

SUPPORTING INFORMATION Additional supporting information may be found online in the Supporting Information section at the end of this article. How to cite this article: de Fátima Yukie Maeda M

Vertical transmission of SARS-CoV2 during pregnancy: A high-risk cohort